chartexchange

Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights

GlobeNewswire Inc. | Nov 9, 2026 7:00 AM EST

Promising Phase 1/2 data from combination study of vopimetostat plus daraxonrasib presented at 2026 ESMO Congress demonstrated 82% objective response rate (ORR) and 88% 9-month progression-free survival (PFS) rate in patients with 2L/3L pancreatic cancer; combination was generally well-tolerated at  go-forward dose

Read original article